Drug Trial Radar · NCT00150800
This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment
Last checked: Nov 20, 2026Latest source record: Aug 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
668
Actual
Start
Jan 2006
Primary completion
Sep 2017
Study completion Sep 2017
Sponsor
- Lead sponsor
- UCB PHARMA Inc. (US)UCB
- Sponsor type
- Industry
- First posted
- Sep 8, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label brivaracetam treatment.
Conditions
- Epilepsy
Interventions
BrivaracetamDrug
* Active Substance: Brivaracetam * Pharmaceutical Form: Tablet * Concentration: 10 mg and 25 mg * Route of Administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) During the Study PeriodTime frame: Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)
- Percentage of Participants Who Withdrew Due to an Adverse Event (AE) During the Study PeriodTime frame: Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)
- Percentage of Participants With a Serious Adverse Event (SAE) During the Study PeriodTime frame: Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)
Locations
100 sites in 6 countries. Site status is shown where the registry gives one.
N01199 1051
Phoenix, Arizona
N01199 1362
Phoenix, Arizona
N01199 1374
Tucson, Arizona
N01199 1050
Little Rock, Arkansas
N01199 1078
Fresno, California
N01199 1392
Newport Beach, California
N01199 1087
San Francisco, California
N01199 1368
San Francisco, California
N01199 1396
Atlanta, Georgia
N01199 1385
Augusta, Georgia
N01199 1356
Chicago, Illinois
N01199 1388
Springfield, Illinois
N01199 1375
Wichita, Kansas
N01199 1364
Lexington, Kentucky
N01199 1380
Louisville, Kentucky
N01199 1052
Paducah, Kentucky
N01199 1083
Ruston, Louisiana
N01199 1373
Baltimore, Maryland
N01199 1086
Bethesda, Maryland
N01199 1077
Burlington, Massachusetts
N01199 1391
Detroit, Michigan
N01199 1395
Detroit, Michigan
N01199 1071
Grand Rapids, Michigan
N01199 1389
Saint Paul, Minnesota
N01199 1079
Tupelo, Mississippi
N01199 1360
Chesterfield, Missouri
N01199 1352
St Louis, Missouri
N01199 1069
Great Falls, Montana
N01199 1062
Toms River, New Jersey
N01199 1053
New York, New York
N01199 1365
Rochester, New York
N01199 1366
Cincinnati, Ohio
N01199 1054
Columbus, Ohio
N01199 1359
Portland, Oregon
N01199 1055
Philadelphia, Pennsylvania
N01199 1059
Philadelphia, Pennsylvania
N01199 1081
Greenville, South Carolina
N01199 1061
Nashville, Tennessee
N01199 1084
Dallas, Texas
N01199 1394
Dallas, Texas
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.